Premium
Cetraxate, a mucosal protective agent, combined with omeprazole, amoxycillin, and clarithromycin increases the eradication rate of Helicobacter pylori in smokers
Author(s) -
Kamada T.,
Haruma K.,
Miyoshi E.,
Mihara M.,
Kitadai Y.,
Yoshihara M.,
Sumii K.,
Kajiyama G.,
Tahara K.,
Mukai T.,
Kawamura Y.,
Hattori N.
Publication year - 2000
Publication title -
alimentary pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.308
H-Index - 177
eISSN - 1365-2036
pISSN - 0269-2813
DOI - 10.1046/j.1365-2036.2000.00807.x
Subject(s) - medicine , clarithromycin , helicobacter pylori , omeprazole , gastroenterology , placebo , amoxicillin , breath test , urea breath test , intention to treat analysis , randomized controlled trial , antibiotics , helicobacter pylori infection , microbiology and biotechnology , pathology , alternative medicine , biology
Background: Our previous study demonstrated that Helicobacter pylori eradication was less effective in smokers than in non‐smokers. Cetraxate is an anti‐ulcer drug that increases gastric mucosal blood flow. Aim: To evaluate the effect of cetraxate combined with new triple therapy for the eradication of H. pylori in smokers. Methods: This study had a single‐centre, double‐blind, randomized non‐placebo design. A total of 106 consecutive H. pylori ‐positive smoking patients were randomly allocated to one of two regimens: one group received omeprazole (20 mg), amoxycillin (1500 mg), and clarithromycin (600 mg) for 7 days (OAC, n =55). The other group recieved OAC plus cetraxate (600 mg) for 7 days (OAC + CET, n =51). The success of H. pylori eradication was evaluated by histology and the 13 C‐urea breath test at 4 weeks after completion of treatment. Results: By intention‐to‐treat analysis, the H. pylori eradication rate was 55% in the OAC group and 92% in the OAC + CET group ( P < 0.01). By per protocol analysis, the H. pylori eradication rate was 58% in the OAC group and 94% in the OAC + CET group ( P < 0.01). Conclusion: Cetraxate combined with new triple therapy increases the eradication of H. pylori in smokers.